Asset profile
CardiAMP
Cell therapy
Evidence outlook · lead readout
NCT02438306 · Heart Failure, Systolic
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT02438306: The study randomized 125 participants to CardiAMP or a sham procedure and masked participants and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Ischemic Heart Failure
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 8 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 17 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CardiAMP: this drug | Phase 3 | Cell therapy | Cardiac cell therapy | ||
| Deramiocel (CAP-1002) | Phase 3 | Cell therapy | Cardiac cell therapy | ||
| HiCM-188 (allogeneic iPSC-Cardiomyocytes) | Phase 3 | Cell therapy | Cardiac cell therapy | ||
| ADR-002K | Phase 2 | Cell therapy | Cardiac cell therapy | ||
| HS-001 | Phase 1/2 | Cell therapy | Cardiac cell therapy | ||
| HucMSC Intramyocardial Therapy | Phase 1/2 | Cell therapy | Cardiac cell therapy | ||
| Anhui HygeianCells EE001 | Phase 1 | Biologic (subtype unspecified) | Cardiac cell therapy | ||
| iPSC-CL | Phase 1 | Cell therapy | Cardiac cell therapy | ||
| STM01 | Phase 1 | Cell therapy | Cardiac cell therapy | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | ||
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 |
…and 53 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
2 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
April 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.